A detailed history of Royal Bank Of Canada transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 5,449 shares of RYTM stock, worth $279,806. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,449
Previous 1,444 277.35%
Holding current value
$279,806
Previous $62,000 259.68%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$35.41 - $44.37 $141,817 - $177,701
4,005 Added 277.35%
5,449 $223,000
Q1 2024

May 15, 2024

SELL
$39.12 - $52.44 $574,594 - $770,238
-14,688 Reduced 91.05%
1,444 $62,000
Q4 2023

Feb 14, 2024

BUY
$21.39 - $49.64 $87,463 - $202,977
4,089 Added 33.95%
16,132 $741,000
Q3 2023

Nov 14, 2023

BUY
$15.81 - $27.8 $75,793 - $133,273
4,794 Added 66.13%
12,043 $276,000
Q2 2023

Aug 14, 2023

BUY
$16.32 - $21.15 $86,267 - $111,798
5,286 Added 269.28%
7,249 $119,000
Q1 2023

May 15, 2023

BUY
$16.88 - $34.24 $30,198 - $61,255
1,789 Added 1028.16%
1,963 $35,000
Q4 2022

Feb 14, 2023

BUY
$22.21 - $30.25 $2,420 - $3,297
109 Added 167.69%
174 $5,000
Q3 2022

Nov 14, 2022

BUY
$4.3 - $30.85 $279 - $2,005
65 New
65 $2,000
Q2 2022

Aug 15, 2022

SELL
$3.12 - $12.25 $8,723 - $34,251
-2,796 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$6.13 - $12.24 $35,155 - $70,196
-5,735 Reduced 67.23%
2,796 $32,000
Q4 2021

Feb 14, 2022

BUY
$8.62 - $13.9 $34,057 - $54,918
3,951 Added 86.27%
8,531 $85,000
Q3 2021

Nov 15, 2021

BUY
$11.68 - $20.72 $4,239 - $7,521
363 Added 8.61%
4,580 $60,000
Q2 2021

Aug 16, 2021

BUY
$18.52 - $22.55 $78,098 - $95,093
4,217 New
4,217 $83,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $2.86B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.